ERBB2 and breast cancer: The prognosis of receptor-mediated targeted therapy in breast cancer is mainly dependent upon the extent of overexpression of the breast cancer-specific cellular receptors particularly human epidermal growth factor receptor-2 (HER2/Neu/ErbB2), estrogen and progesterone receptors.